荧光定量聚合酶链反应检测Bcl-2在乳腺癌临床应用

The clinical application of fluorescent quantification polymerase chain reaction to detect Bcl-2 in the diagnosis of breast cancer

目的建立荧光定量聚合酶链反应(FQ-PCR)法检测Bcl-2基因表达水平,探讨其在乳腺癌诊断和治疗监测中的应用。方法建立FQ-PCR法,并以β2-微球蛋白为内对照测定30名健康女性体检者、30例良性乳腺疾病患者和以及随访5年以上81例乳腺癌患者外周血中Bcl-2的表达量。结果 Bcl-2表达水平在正常对照组和良性乳腺疾病组间差异无统计学意义(P>0.05),乳腺癌组均高于前两组(P<0.05),β2-微球蛋白在三组间差异无统计学意义(P>0.05)。81例乳腺癌患者阳性率为58.0%,良性乳腺疾病组为0。Bcl-2表达与患者年龄和肿瘤大小和类型无关(P>0.05),与乳腺癌组织学分级和预后相关(P<0.05)。结论 FQ-PCR技术是高度灵敏、高度特异的快速定量检测Bcl-2方法,可有效监测乳腺癌的诊断、疗效、转移和预后。乳腺癌Bcl-2蛋白表达阳性提示肿瘤分化程度高,患者预后好。

Objective To evaluate the clinical application of fluorescent quantification polymerase chain reaction（FQ-PCR） to detect Bcl-2 in the diagnosis of breast cancer.Methods Bcl-2 in the of clinical samples of 30 health women,30 patients with benign breast disease and 81 cases of breast cancer patients with ≥ 5 years of follow up were detected by FQ-PCR.β2-microglobin was used as internal control.Results There were no significant difference in Bcl-2/β2-microglobin between normal controls and benign breast disease group（P0.05）.Bcl-2/β2-microglobin in breast cancer group were higher than those in the other groups（P0.05）.There were no difference in β2-microglobin among three groups（P0.05）.The positive ratio of breast cancer and benign disease were 58.0 and 0 percent respectively.No significant association of Bcl-2 expression among age and tumor size and type was noted（P0.05）,but its expression in breast cancer was correlated with histological grade and prognosis（P0.05）.Conclusion FQ-PCR is a rapid and sensitive and specific method for quantitating Bcl-2.It also gives objective evidence to the diagnosis,therapy,metastasis of breast cancer.Expression of bcl-2 occurs more frequently in well differentiated breast cancer.It is associated with better prognosis of the patients.